Literature DB >> 27221930

Formulation and Cytotoxicity of Ribosome-Inactivating Protein Mirabilis Jalapa L. Nanoparticles Using Alginate-Low Viscosity Chitosan Conjugated with Anti-Epcam Antibodies in the T47D Breast Cancer Cell Line.

Psycha Anindya Wicaksono1, Sismindari Name, Ronny Martien, Hilda Ismail.   

Abstract

Ribosome-inactivating protein (RIP) from Mirabilis jalapa L. leaves has cytotoxic effects on breast cancer cell lines but is less toxic towards normal cells. However, it can easily be degraded after administration so it needs to be formulated into nanoparticles to increase its resistance to enzymatic degradation. The objectives of this study were to develop a protein extract of M. jalapa L. leaves (RIP-MJ) incorporated into nanoparticles conjugated with Anti-EpCAM antibodies, and to determine its cytotoxicity and selectivity in the T47D breast cancer cell line. RIP-MJ was extracted from red-flowered M. jalapa L. leaves. Nanoparticles were formulated based on polyelectrolyte complexation using low viscosity chitosan and alginate, then chemically conjugated with anti-EpCAM antibody using EDAC based on carbodiimide reaction. RIP-MJ nanoparticles were characterised for the particle size, polydispersity index, zeta potential, particle morphology, and entrapment efficiency. The cytotoxicity of RIP-MJ nanoparticles against T47D and Vero cells was then determined with MTT assay. The optimal formula of RIP-MJ nanoparticles was obtained at the concentration of RIP-MJ, low viscosity chitosan and alginate respectively 0.05%, 1%, and 0.4% (m/v). RIP-MJ nanoparticles are hexagonal with high entrapment efficiency of 98.6%, average size of 130.7 nm, polydispersity index of 0.380 and zeta potential +26.33 mV. The IC50 values of both anti-EpCAM-conjugated and non-conjugated RIP-MJ nanoparticles for T47D cells (13.3 and 14.9 μg/mL) were lower than for Vero cells (27.8 and 33.6 μg/mL). The IC50 values of conjugated and non- conjugated RIP-MJ for both cells were much lower than IC50 values of non-formulated RIP-MJ (>500 μg/mL).

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27221930     DOI: 10.7314/apjcp.2016.17.4.2277

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  4 in total

Review 1.  Drug Delivery of Natural Products Through Nanocarriers for Effective Breast Cancer Therapy: A Comprehensive Review of Literature.

Authors:  Kah Min Yap; Mahendran Sekar; Shivkanya Fuloria; Yuan Seng Wu; Siew Hua Gan; Nur Najihah Izzati Mat Rani; Vetriselvan Subramaniyan; Chandrakant Kokare; Pei Teng Lum; M Yasmin Begum; Shankar Mani; Dhanalekshmi Unnikrishnan Meenakshi; Kathiresan V Sathasivam; Neeraj Kumar Fuloria
Journal:  Int J Nanomedicine       Date:  2021-12-02

Review 2.  A new age for biomedical applications of Ribosome Inactivating Proteins (RIPs): from bioconjugate to nanoconstructs.

Authors:  Elio Pizzo; Antimo Di Maro
Journal:  J Biomed Sci       Date:  2016-07-20       Impact factor: 8.410

3.  Folate-Targeted Nanostructured Lipid Carriers (NLCs) Enhance (Letrozol) Efficacy in MCF-7 Breast Cancer Cells

Authors:  Mehdi Sabzichi; Jamal Mohammadian; Ahmad Yari Khosroushahi; Roya Bazzaz; Hamed Hamishehkar
Journal:  Asian Pac J Cancer Prev       Date:  2016-12-01

Review 4.  Chitosan-Based Nanoparticles of Targeted Drug Delivery System in Breast Cancer Treatment.

Authors:  Yedi Herdiana; Nasrul Wathoni; Shaharum Shamsuddin; I Made Joni; Muchtaridi Muchtaridi
Journal:  Polymers (Basel)       Date:  2021-05-24       Impact factor: 4.329

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.